{"name":"Yuhan Corporation","slug":"yuhan","ticker":"000100.KS","exchange":"KRX","domain":"yuhan.co.kr","description":"Yuhan Corporation is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.","hq":"Seoul, South Korea","founded":1919,"employees":"~75,000","ceo":"Wook Je Cho","sector":"Oncology / NASH / Branded Generics","stockPrice":94200,"stockChange":2800,"stockChangePercent":3.06,"marketCap":"$7.0T","metrics":{"revenue":2186637606912,"revenueGrowth":10.1,"grossMargin":33.3,"rdSpend":0,"netIncome":194079178752,"cash":378081214464,"dividendYield":0.66,"peRatio":29.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Yuhan's NASH Treatment patent cliff ($100M at risk)","drug":"Yuhan's NASH Treatment","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Yuhan Corporation Reports 2023 Q4 Earnings","summary":"Yuhan Corporation reported its 2023 Q4 earnings, with revenue increasing by 10% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"Yuhan Corporation Partners with [Partner Company] for NASH Treatment","summary":"Yuhan Corporation partnered with [Partner Company] to develop a new treatment for NASH.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOU212bjktRDk0bnhIdE94TUg5VlVLaFQ0dkctOFk2RTROVzhRZExPMDZQVUkwQUdKaTRvdUVlTjJmUDFpTkdtWnNNQ3o3QnI5TDI3bExTdmNYQlB3UklIRzJkTUJiLWdERUtaSEFIenNTYnZpMlFPSTRycVRzRERyQTlqaEpXc1RKQ1ZVUHlpaVJENERnbXc?oc=5","date":"2026-03-30","type":"deal","source":"Seoul Economic Daily","summary":"Korean Pharma Firms Acquire VCs to Drive Drug and Healthcare Investments - Seoul Economic Daily","headline":"Korean Pharma Firms Acquire VCs to Drive Drug and Healthcare Investments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNd0h1ZWI1X3ZPa3pxSVlPUkctRFF1NklObkRDSkdoYzlQZy0wVGwwRVBveTM4UkVnT0NGUlNuZmg3dkR1cFpaeFpQWkNsdldtRnh4OWdLWW9jNUcxbDRrQkNnVUZmMHJWNU5WMENubUZocTEyeElIMGs0MG5BUHZjNmpWXzEwdGVySVZsNWF1XzNwZndJTUNoWTNXemJHMkU?oc=5","date":"2026-03-29","type":"deal","source":"Seoul Economic Daily","summary":"Korean Pharma Firms Acquire VCs to Invest Directly in Drugs, Cosmetics, Medical Devices - Seoul Economic Daily","headline":"Korean Pharma Firms Acquire VCs to Invest Directly in Drugs, Cosmetics, Medical Devices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPWEJuOVhIQnNTZlE0bExDbFJ3UVJsTVhwamt5c1pkblA3bnNZTHpWQWU0eXo5WHlWYXR0M05TTldfTDNTNEZUdGJ6aDlUM3pMb1dRMzB6VVg3RHVXRDZ4Y1lrNGNhU2N3NGVTYXBWWm9zTmt0Vk51T21mMjR0aG5mQjA2a3dJcVBjaFBiRGlMUG9OU2lENk5DaHAxOW45SnJo?oc=5","date":"2026-02-07","type":"pipeline","source":"Seoul Economic Daily","summary":"Yuhan Subsidiary Immun'Oncé Stock Plunges 20% After Surprise Rights Offering - Seoul Economic Daily","headline":"Yuhan Subsidiary Immun'Oncé Stock Plunges 20% After Surprise Rights Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOZndIdlFsaU9SaDhrRnpNblJvUVRlWVlTNFJCMmR1UWEwT0VaaXlUWDEyTzJySFZ4S2MwRlh1T19vbDBpRmZ2c3JvZGFNNEtNQzhVZVFkUlZ5MXNJYXRaaFZLT1U3MHR5VlVvUVRGQ05meE43WXppalRKV0E3NXNyU3VPNDFscGpnQUhZM0FLM2ZFT1Y1bTZqLWRzUDQ?oc=5","date":"2026-02-02","type":"earnings","source":"Seoul Economic Daily","summary":"Yuhan Corporation Seen as Promising Despite Short-Term Earnings Slump - Seoul Economic Daily","headline":"Yuhan Corporation Seen as Promising Despite Short-Term Earnings Slump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOZDhWbFh4VmtvUVhWYU9HczZBTUFfMUp0amhEMURPbGFVM2RXcUUwLThUN2d1TGE4Y0E4Z0NwdS1vdnVaZ3pVelhNdWRaRFJWVmUzXzQ2bkpaTDAyc0d0MlFhY1o4bTdMVExvSEtkQWprRGZJZlZyNkJiTkJoM1gxVzEyWXFJTDBVYy1KZnRPX25zUnhtdy1SNmt2Szd5Uk5XUksydQ?oc=5","date":"2026-01-21","type":"pipeline","source":"Seoul Economic Daily","summary":"Yuhan Corporation to Launch 'NewCo' Model for Drug Development - Seoul Economic Daily","headline":"Yuhan Corporation to Launch 'NewCo' Model for Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOMXNocUN1Z2Ztd0M1aUtKZmVWbmtidk90UmlCems3TmxOU01kSGt1cV9fbjh6dF9sYUljcnBzMDVndUZyZFJrZlNnMEo0c0hYb0o0V1lCaXAtZ0tkUWhEQ2ppbmRNc2w1aUt2dFIzdU9UUnJfNzBKNWhwMjk1dC1mWkh4ajE4TkhyWHNqNjU4eGtkWk1QUVNj?oc=5","date":"2026-01-18","type":"trial","source":"Seoul Economic Daily","summary":"Inventage Lab to Begin Clinical Trials for Monthly Injectable Obesity Drug with Yuhan - Seoul Economic Daily","headline":"Inventage Lab to Begin Clinical Trials for Monthly Injectable Obesity Drug with Yuhan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBVM3JrVFpaLWN5TlQ5bFFDa2g4aUhpWmJGeVYxUkZvYnlTTkVOUjU1UWhab283QnRZZzV5OEZuWjd1WjllQTR6VmdiYkMzcGhibVBuM3B0RUo?oc=5","date":"2017-08-21","type":"pipeline","source":"Yahoo Finance Australia","summary":"Hanmi Science Co., Ltd. (008930.KS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Hanmi Science Co., Ltd. (008930.KS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5sWGs5MXJ2Ul9JekxWemN3cldfM3ItODBZQ1lSQ3F0dkl5a2ZiZEt2aWFXTE1KRU85LVhDb3pmNjA5SUdBYXZmMkRJdU5OR0JFc2JvUERWVDA?oc=5","date":"2017-06-13","type":"pipeline","source":"Yahoo Finance Singapore","summary":"GC Biopharma Corp. (006280.KS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"GC Biopharma Corp. (006280.KS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRzV0RkV0Sk4zN19JR3Q1Z2V6aEZNVVZ5WWxPcVZsRDIzbkVQbTRpa09aN1lPdFBWN1BzczlueXE5Zmx5MTdtY2gyUHJSd05vOTlibEVTQlhqbTh0OHc5V0NsRVRXdG50TjNyc1FIMjllTWdHTkNuY3BIcHVPSjZqc3NFM1pJaHBsV040Rl9pN2llMEFLcFc3UkFlcHR4NU9QbG5LdHhjcDVYTzVTQU1KRGw4clRzSnFQazhiR19OLVpJV0Jwa2dFdzNUaE1zR0lNYThQZTd3bw?oc=5","date":"2016-03-02","type":"pipeline","source":"PR Newswire","summary":"Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia - PR Newswire","headline":"Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia","sentiment":"neutral"}],"patents":[{"drugName":"Yuhan's NASH Treatment","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Samsung Biologics","Celltrion","Hanmi Pharmaceutical"],"therapeuticFocus":["Oncology","NASH","Branded Generics"],"financials":null,"yahoo":{"currentPrice":94200,"previousClose":91400,"fiftyTwoWeekHigh":136400,"fiftyTwoWeekLow":91600,"fiftyTwoWeekRange":"91600.0 - 136400.0","fiftyDayAverage":103546,"twoHundredDayAverage":112741.5,"beta":0.57,"enterpriseValue":6853957255168,"forwardPE":29.6,"priceToBook":0,"priceToSales":3.22,"enterpriseToRevenue":3.13,"enterpriseToEbitda":39.28,"pegRatio":0,"ebitda":174468988928,"ebitdaMargin":8,"freeCashflow":-95031836672,"operatingCashflow":106227392512,"totalDebt":343156359168,"debtToEquity":14.5,"currentRatio":2.06,"returnOnAssets":2.1,"returnOnEquity":8.2,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":19,"targetMeanPrice":144157.89,"targetHighPrice":180000,"targetLowPrice":81000,"dividendRate":600,"payoutRatio":0,"fiveYearAvgDividendYield":0.58,"exDividendDate":1772064000,"insiderHeldPercent":23.9,"institutionHeldPercent":19,"sharesOutstanding":73615781,"floatShares":61911421,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":29287.98,"bookValue":0,"officers":[{"age":70,"name":"Mr. Wook-Je  Cho","title":"President, CEO & Executive Director"},{"age":66,"name":"Mr. Yeul-Hong  Kim","title":"President, R&D Director & Executive Director"},{"age":67,"name":"Mr. Byung-Man  Lee","title":"VP, Head of the Mngt. HQ. & Internal Accounting Manager"},{"age":58,"name":"Mr. Joo-Yong  Chung","title":"MD & Head of Marketing Department"},{"age":57,"name":"Mr. Jae-Kyo  Kim","title":"VP & Head of the Pharmaceutical Business Division"},{"age":61,"name":"Mr. Sung-Soo  Kim","title":"MD & Head of the Lifestyle Health Business Division"},{"age":50,"name":"Mr. Jun-Hwan  Kim","title":"MD & Head of Biopharmaceutical Division"},{"age":60,"name":"Mr. Min Chul  Cho","title":"MD & ESG Management Director"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.yuhan.co.kr","phone":"82 2 828 0181"}}